Therapeutic Hypothermia Systems - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The therapeutic hypothermia systems market size was valued at USD 324.17 million in 2025 and is estimated to grow from USD 344.47 million in 2026 to reach USD 473.87 million by 2031, at a CAGR of 6.59% during the forecast period (2026-2031). This report is Segmented by Product (Intravascular Cooling Catheters, Surface Systems, Esophageal Devices, Selective Head Cooling Caps, Immersion/Convective Systems), Application (Post-Cardiac Arrest, Neonatal HIE, Ischemic Stroke, TBI), End User (Hospitals, Ascs, EMS, Research Institutes), and Geography (North America, Europe, and More). Market Forecasts are Provided in Value (USD).

Global Therapeutic Hypothermia Systems Market Trends and Insights

Post-Cardiac Arrest Temperature Control Codified in AHA/ERC Protocols

AHA 2025 Advanced Cardiovascular Life Support guidance preserved a Class I recommendation for temperature control within 32-36 °C for at least 24 hours, while the 2025 ERC-ESICM update emphasized fever prevention for 72 hours. North American ICUs still rely on intravascular catheters for precise core cooling, but many European units now favor surface pads that sustain normothermia without the infection risk of venous access. A 2025 survey of 1,200 European ICUs reported that one-third had adopted the new ERC practice, propelling demand for gel-free adhesive pads. Vendors therefore market consoles able to switch between deep cooling and normothermia, aligning with divergent regional protocols. Compliance with IEC 60601 electrical safety norms remains mandatory across markets, bolstering buyer confidence.

Neonatal HIE Hypothermia Standardized at 33-34 °C

The American Academy of Pediatrics reaffirmed the HIE cooling window in 2026, citing a 25% reduction in mortality or disability at 18 months when therapy starts within 6 hours of birth and lasts 72 hours. India’s National Neonatology Forum endorsement in 2024 catalyzed demand for locally built cradle systems priced below USD 1,000, replacing improvised ice packs in tier-2 hospitals. Asia-Pacific NICU upgrades underscore the need for readily deployable devices that integrate rectal probes and servo regulators. Yet, uptake remains patchy in sub-Saharan Africa, where WHO 2024 guidelines still recommend passive cooling when servo-control is unavailable. Continuous temperature monitoring and trained staff thus remain critical barriers.

TTM2-Era Evidence De-Emphasizes Deep Hypothermia

The TTM2 trial, reinforced by 2024 subgroup analysis, confirmed no survival benefit from 33 °C versus normothermia after cardiac arrest. European and Australasian ICUs rapidly updated protocols, curbing demand for high-intensity catheter systems. With less aggressive cooling, hospitals reduce disposable catheter spend of USD 1,500-2,500 per case in favor of reusable pads. Vendors now highlight fever prevention features rather than neuroprotection, reshaping marketing narratives across the therapeutic hypothermia systems market.

Other drivers and restraints analyzed in the detailed report include:

• High Incidence of OHCA and Neuro Emergencies Sustains Demand
• Asia-Pacific Healthcare Expansion Accelerates Uptake
• Hypothermia-Related Arrhythmias and Adverse Events

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, intravascular catheters generated 30.91% of therapeutic hypothermia systems market revenue thanks to rapid 2.5 °C-per-hour cooling and servo accuracy of ±0.2 °C. Yet safety recalls and thrombotic risk diverted many European ICUs toward water-circulating pads and gel-free blankets, accelerating surface-system shipments. Immersion and convective devices, priced below USD 10,000, are projected to grow at a 7.22% CAGR, targeting cost-conscious hospitals in Latin America and Southeast Asia. Esophageal platforms such as ensoETM offer continuous OR-to-ICU control and avoid central-line infections, appealing to electrophysiology labs. Selective head caps remain a neonatal niche, yet the dominant intravascular share highlights clinicians’ trust in core-target accuracy when deep cooling is still required.

Although performance shifts favor lower-cost alternatives, many centers keep catheter consoles to manage outlier cases needing aggressive target drops. ZOLL’s 2024 integrated Thermogard console, which toggles between catheter and pad circuits, exemplifies hybrid design that future-proofs procurement decisions. The therapeutic hypothermia systems industry therefore faces dual pressures: sustain premium consumable yield while proving life-cycle cost advantages against rising immersion-system incumbents.

Complete Report Scope:

• By Product
  • Intravascular cooling catheters (IVTM)
  • Surface systems (water-circulating pads/blankets/garments)
  • Esophageal temperature management devices
  • Selective head cooling caps
  • Immersion/convective systems
• By Application
  • Post-cardiac arrest
  • Neonatal hypoxic-ischemic encephalopathy (HIE)
  • Ischemic stroke
  • Traumatic brain injury (TBI) and neurogenic fever
• By End User
  • Hospitals (ICUs and Emergency Departments)
  • Ambulatory surgical centers and specialty clinics
  • Emergency medical services (pre-hospital)
  • Academic and research institutes
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 45.35% of 2025 revenue, underwritten by more than 350,000 OHCAs per year, DRG-based reimbursement and a dense network of Level I trauma centers. A 2025 survey revealed 60% of U.S. ICUs shifted to normothermia within 18 months of TTM2, spurring surface-pad sales. Recall-driven diversification also helped newer entrants secure contracts as hospitals reduced single-vendor dependency.

Europe follows ERC guidance favoring fever suppression for 72 hours and has consequently leaned into non-invasive pads and immersion baths. Yet Germany and Switzerland still procure catheter consoles for centers performing percutaneous coronary interventions around the clock. IEC-60601 and MDR requirements keep barriers high for small suppliers, but BrainCool AB’s 2023 IQool update showed that safety-centric brands can win adoption across Scandinavian stroke units.

Asia-Pacific is pacing the therapeutic hypothermia systems market at an 8.3% CAGR through 2031, lifted by ICU bed additions in China and India, Malaysia’s 2025 IQool clearance and neonatal HIE protocols across ASEAN. However, markets are bifurcated: Japan’s stroke-heavy demographic relies on normothermia pads, whereas Bangladesh and Sri Lanka depend on sub-USD 1,000 passive cradles due to constrained capital budgets. The Gulf states in the Middle East are expanding critical-care capacity, and Qatar’s 2025 registry reported a 17.8% discharge survival comparable to high-income benchmarks. In South America, Brazil and Argentina anchor demand, but currency swings hamper long-term procurement planning. Overall, regulatory harmonization is advancing faster than reimbursement unification, leaving vendors to tailor financing schemes per country.

List of Companies Covered in this Report:

• 3T Medical Systems
• Beckton Dickinson
• Belmont Medical Technologies
• BrainCool AB
• EMCOOLS Medical Cooling Systems
• EM-MED Sp. z o.o.
• Gentherm
• Haemonetics Corporation (Attune Medical)
• Inspiration Healthcare Group plc
• International Biomedical Ltd.
• Life Recovery Systems
• pfm medical hico gmbh (HICO)
• Phoenix Medical Systems
• Pluss Advanced Technologies (MiraCradle)
• Seiratherm GmbH
• VNG Medical Innovation System Pvt. Ltd.
• ZOLL Medical Corporation (Asahi Kasei)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support